Journal
SCIENTIFIC REPORTS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-18118-7
Keywords
-
Categories
Funding
- Jane and Aatos Erkko Foundation
- Finnish Cultural Foundation [00160159]
- Turku Doctoral Programme of Molecular Medicine
- Academy of Finland
Ask authors/readers for more resources
Therapeutic resistance to kinase inhibitors, particularly in glioblastoma, is a major challenge in cancer treatment. Researchers have developed an actionable targets of multi-kinase inhibitors (AToMI) strategy to identify target kinases involved in the therapeutic effects of multi-kinase inhibitors. Using this strategy, they successfully characterized AKT and mitochondrial pyruvate dehydrogenase kinase PDK1 and PDK4 as target kinases of staurosporine derivatives that synergized with PP2A activation in glioblastoma cells.
Therapeutic resistance to kinase inhibitors constitutes a major unresolved clinical challenge in cancer and especially in glioblastoma. Multi-kinase inhibitors may be used for simultaneous targeting of multiple target kinases and thereby potentially overcome kinase inhibitor resistance. However, in most cases the identification of the target kinases mediating therapeutic effects of multi-kinase inhibitors has been challenging. To tackle this important problem, we developed an actionable targets of multi-kinase inhibitors (AToMI) strategy and used it for characterization of glioblastoma target kinases of staurosporine derivatives displaying synergy with protein phosphatase 2A (PP2A) reactivation. AToMI consists of interchangeable modules combining drug-kinase interaction assay, siRNA high-throughput screening, bioinformatics analysis, and validation screening with more selective target kinase inhibitors. As a result, AToMI analysis revealed AKT and mitochondrial pyruvate dehydrogenase kinase PDK1 and PDK4 as kinase targets of staurosporine derivatives UCN-01, CEP-701, and K252a that synergized with PP2A activation across heterogeneous glioblastoma cells. Based on these proof-of-principle results, we propose that the application and further development of AToMI for clinically applicable multi-kinase inhibitors could provide significant benefits in overcoming the challenge of lack of knowledge of the target specificity of multi-kinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available